Titel

Merkliste
1 Ergebnisse

Long-term tolerability and efficacy after initial PegIFN-α ..:

Flygt, Hjalmar ; Söderlund, Stina ; Stentoft, Jesper...
https://pure.au.dk/portal/da/publications/longterm-tolerability-and-efficacy-after-initial-pegifn-addition-to-dasatinib-in-cmlcp(12ec8ae0-525f-42a6-8df6-bcd95252bcb7).html. , 2021

Link: https://pure.au.dk/portal/da/publications/longterm-tol..

RT Journal
T1 <Title>Long-term tolerability and efficacy after initial PegIFN-α addition to dasatinib in CML-CP:Five-year follow-up of the NordCML007 study</Title>

UL https://suche.suub.uni-bremen.de/peid=base-ftuniaarhuspubl:oai:pure.atira.dk:publications_12ec8ae0-525f-42a6-8df6-bcd95252bcb7&Exemplar=1&LAN=DE
				
A1 Flygt, Hjalmar
A1 Söderlund, Stina
A1 Stentoft, Jesper
A1 Richter, Johan
A1 Koskenvesa, Perttu
A1 Mustjoki, Satu
A1 Majeed, Waleed
A1 Lübking, Anna
A1 Dreimane, Arta
A1 Markevärn, Berit
A1 Stenke, Leif
A1 Myhr Eriksson, Kristina
A1 Gjertsen, Bjørn Tore
A1 Gedde-Dahl, Tobias
A1 Dimitrijevic, Andreja
A1 Udby, Lene
A1 Olsson-Strömberg, Ulla
A1 Hjorth-Hansen, Henrik
YR 2021
K1 BCR-ABL Positive
K1 chronic myelogenous leukemia
K1 clinical trial
K1 dasatinib
K1 interferon-alpha
K1 SURVIVAL
K1 TREATMENT-FREE REMISSION
K1 INTERFERON-ALPHA-2B
K1 PHASE-2
K1 COMBINATION
K1 CHRONIC MYELOID-LEUKEMIA
K1 TRIAL
K1 IMATINIB
K1 MOLECULAR RESPONSE
K1 FRONTLINE NILOTINIB
JF https://pure.au.dk/portal/da/publications/longterm-tolerability-and-efficacy-after-initial-pegifn-addition-to-dasatinib-in-cmlcp(12ec8ae0-525f-42a6-8df6-bcd95252bcb7).html
LK http://dx.doi.org/https://pure.au.dk/portal/da/publications/longterm-tolerability-and-efficacy-after-initial-pegifn-addition-to-dasatinib-in-cmlcp(12ec8ae0-525f-42a6-8df6-bcd95252bcb7).html
DO https://pure.au.dk/portal/da/publications/longterm-tolerability-and-efficacy-after-initial-pegifn-addition-to-dasatinib-in-cmlcp(12ec8ae0-525f-42a6-8df6-bcd95252bcb7).html
SF ELIB - SuUB Bremen

Export

RefWorks (nur Desktop-Version!)
Flow (Zuerst in Flow einloggen, dann importieren)